Company / Operating Cash Flow per Share
Avalo Therapeutics, Inc. Operating Cash Flow per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$4.91
FY2025
5-year range
-$780.78 / -$0.95
FY2021-FY2025
Trend
+92.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-780.78 to $-4.91 over the past 2 years.
Based on SEC 10-K filings.
-4.91 in FY2025.
Improved from $-780.78 to $-4.91 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 92.0% year-over-year.
- Peak operating cash flow per share was recorded in FY2017.
- Lowest operating cash flow per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.91 | +92.0% |
| FY2024 | -$61.19 | +92.2% |
| FY2023 | -$780.78 | -27334.3% |
| FY2022 | -$2.85 | -201.1% |
| FY2021 | -$0.95 | -3.5% |
| FY2020 | -$0.91 | -94.8% |
| FY2019 | -$0.47 | -368.7% |
| FY2018 | -$0.10 | -107.5% |
| FY2017 | $1.33 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026